1988•Unpublished venueRequires access
The effect of gemfibrozil in patients with primary hyperlipidemia
Yi Xu
Open publisher page 0 citations
Abstract
The activity of gemfibrozil was studied in 53 patients with primary hyperlipidemia. At the end of 12 weeks' treatment, the drug significantly reduced the total serum Cholesterol by 17%, and serum triglycerides 65% while the high density lipoprotein cholesterol raised by 0.7 mmol/1.There was no miserable adverse reaction. Results indicated that gemfibrozil is an effective lipid regulator recently discovered.